Today the Innovation Fund Denmark (innovationsFonden) granted 1 million DKK over 3 years to VAR2 Pharmaceuticals and Copenhagen University to fund an Industry PhD student in the project “Cancer immunotherapy based on a malaria protein”. We are very happy for the grant and look forward to work with the talented soon-to-be new PhD student Jessica […]
Var2 Pharmaceuticals has been selected as the European winner of the 2020 Advance Biotech Grant Program (SigmaMillipore). VAR2 Pharmaceuticals was chosen for its development of a promising novel pre-clinical cancer drug-conjugate treatment with the potential to treat multiple types of human adult and childhood solid tumors.
On May 7th, Bloom Burton & Co. announced that VAR2 Pharmaceuticals’ co-founder and member of the Board, Prof. Poul Sorensen, is one of the three final nominees to the prestigious 2019 Bloom Burton Award, honouring individuals making the greatest contributions to Canada’s healthcare industry in the past years. We are very proud of having Poul on […]
On May 7th, Bloom Burton & Co. announced that VAR2 Pharmaceuticals’ co-founder and member of the Board, Prof. Poul Sorensen, is one of the three final nominees to the prestigious 2019 Bloom Burton Award, honouring individuals making the greatest contributions to Canada’s healthcare industry in the past years. We are very proud of having Poul on […]
Our Research Scientist Dr. Nader Al-Nakouzi, will present new exciting data on oncofetal Chondrotin sulfat A in prostate cancer at the Cellular signalling and cancer therapy EMBO workshop, taking place in Cavtat, Croatia 14-18 September 2018.
It is with great pleasure we can announce that Dr. Nader Al-Nakouzi was awarded The FEBS Journal Best Poster Prize for the poster “Expression and regulation of oncofetal chondroitin sulfate in prostate cancer” at the Cellular signalling and cancer therapy EMBO workshop in Cavtat, Croatia 14-18 September 2018.
Co-founder and executive Chairman of the Board of directors, Dr. Mads Daugaard, are to present data on VAR2-based immunotherapy in the context of the cancer microenvironemnt at the 9th CDD Conference on Cancer, taking place in London, September 17-19, 2018. The title of the talk is “Targeting oncofetal glycosaminoglycans in the tumor microenvironment”.
VarCT Diagnostics/VAR2 Pharmaceuticals will be at the Nordic Life Science Days in Stockholm 10-12 September 2018. We look forward to meet old and new partners in the Life Science business.
Today our researchers at Copenhagen University and University of British Columbia together with academic partners in United Kingdom, Australia and Taiwan published an article in Nature Communications that demonstrates that rVAR2 indeed can be used as a tool to capture and isolate circulating tumour cells (CTCs) of various types. This is an important event also […]
Check out the article about VAR2 Pharmaceuticals and VarCT Diagnostics here.
Our website only uses strictly necessary cookies. Please consult our Privacy Policy for additional information on how we process your data.